Promising mesothelioma drug trial pulled before it even started
NCT ID NCT06654050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alrizomadlin (APG-115)
- What this could lead to
- If it works, this could point toward a treatment that slows or stops early mesothelioma growth in people with BAP1 cancer syndrome.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results are available. It is unknown if the drug is safe or effective for this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Engineered immune cells take aim at Mesothelin-Positive tumors